Protalix CEO confident data submission will address US FDA concerns for Gaucher's drug
This article was originally published in Scrip
Executive Summary
Investors felt somewhat reassured that Protalix BioTherapeutics had satisfactorily dealt with requests for additional data outlined by US regulators in a February complete response letter (CRL) for the Carmiel, Israel-based firm's investigational Gaucher's disease drug taliglucerase alfa, giving the company's shares a 3.6% boost on 1 August in US trading, or 23 cents, before closing at $6.64, a gain of 20 cents, or 3.1%.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.